ASC
The 10th ASC Student Supercomputer Challenge (ASC) Finals recently concluded at the University of Science and Technology of China (USTC) in Hefei. For the onsite competition, Peking University emerged as the overall Champion, while USTC secured the Silver Prize and e Prize, marking a remarkable achievement. Zhejiang University was honored with the Highest LINPACK award, alongside several other teams who garnered prestigious honors. In the virtual competition, the team from the Chinese University of Hong Kong emerged as the champion, while the teams from the Chinese University of Hong Kong, National Tsing Hua University, and Kasetsart University were recognized with the Application Innovation Award.
Over 300 teams from universities worldwide participated in the 10th ASC Student Supercomputer Challenge. Following the preliminary contests, the Top 24 teams advanced to the finals. Among them, the Top 20 teams from the Chinese mainland competed onsite, while others engaged in virtual participation through the AWS cloud computing platform.
During the finals, teams showcased their prowess by designing and constructing cluster systems with a maximum power consumption of 3,000 W. Furthermore, they were tasked with running and optimizing cutting-edge scientific and engineering applications, such as HPL and HPCG benchmarks, Large Language Model, DeePMD, WRF-Hydro, and FVCOM. Remarkably, the 10th ASC featured a group competition, with 24 teams divided into 4 groups, tackling the current application of random quantum circuit sampling simulation.
The competition reached its pinnacle with Peking University ultimately clinching the coveted Champion title. The team demonstrated exceptional performance across various tasks, including WRF-Hydro and DeePMD, showcasing profound expertise in comprehensive supercomputing systems, applications, and outstanding optimization abilities. Meanwhile, the USTC team secured the Silver Prize, excelling in tasks such as Large Language Model and HPL&HPCG benchmarks.
USTC's team delivered outstanding results in the challenging Large Language Model task, employing cutting-edge large model parallel strategies, computing acceleration algorithms, and video memory optimization techniques. Their considerations of training speed and loss-convergence led to the team's remarkable performance, earning them the esteemed e Prize.
Zhejiang University's team, operating within the specified 3,000W power consumption limit, attained an impressive floating-point performance of 109 TFLOPs, ultimately securing them the Highest LINPACK award.
A collaborative effort by the Southern University of Science and Technology, Lanzhou University, Shanghai Jiao Tong University, Qilu University of Technology, and the Chinese University of Hong Kong resulted in efficient optimization of random quantum circuit sampling simulation. Their commendable efforts were rewarded with the Group Competition Award.
Furthermore, Qinghai University's outstanding performance earned them the Application Innovation Award.
Jack Dongarra, Member of US National Academy of Engineering, winner of the Turing Award, Distinguished Professor at the Oak Ridge National Laboratory and the University of Tennessee, and ASC Advisory Committee Chair said in the 10th ASC Student Supercomputer Challenge Finals’ closing ceremony, "The goal of the ASC Student Supercomputer Challenge is to foster the next generation of young talent, to inspire exploration, innovation, and collaboration in supercomputing and AI. Your efforts in designing, building, tuning, and optimizing your HPC systems, benchmarks and real scientific applications with a 3 kilowatt power cap are truly inspirational."
About ASC
The ASC Student Supercomputer Challenge stands as the world's most extensive competition in student supercomputing, expertly organized and sponsored by the Asia Supercomputer Community with support from esteemed institutions and experts across Asia, Europe, and America. ASC's primary goals encompass fostering international exchange and training for budding supercomputing talents, enhancing applications and research capabilities in the field, propelling the advancement of supercomputing technologies, and stimulating technical and industrial innovation. Since its inception in 2012, the ASC Student Supercomputer Challenge has attracted close to 10,000 undergraduate participants hailing from all corners of the globe. Learn more about ASC at http://asc-events.org/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230518005351/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release
Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe7.1.2026 08:30:00 CET | Press release
Exclusive agreement covers 13 Central and Eastern European markets Collaboration will help expand access to VANFLYTA for patients with newly diagnosed FLT3-ITD positive AML Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). Under the terms of the agreement, Daiichi Sankyo will be responsible for the manufacturing and supply of VANFLYTA while GENESIS Pharma will lead medical affairs, market access and commercialization efforts in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. Financial terms of the agreement are not being disclosed. VANFLYTA was approved in the EU in November 2023 for the treatment of adult patients with newly diagnose
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
